CSIMarket
 
Applied Dna Sciences Inc  (NASDAQ: APDN)
Other Ticker:  
 
    Sector  Technology    Industry IT Infrastructure
   Industry IT Infrastructure
   Sector  Technology
 
Price: $0.1689 $0.00 -0.822%
Day's High: $0.1719 Week Perf: -0.76 %
Day's Low: $ 0.17 30 Day Perf: -25.92 %
Volume (M): 1,081 52 Wk High: $ 14.40
Volume (M$): $ 183 52 Wk Avg: $2.62
Open: $0.17 52 Wk Low: $0.12



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 4
 Employees 50
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Applied Dna Sciences Inc
Applied DNA Sciences Inc is a biotechnology company that specializes in utilizing DNA-based technologies to address unique challenges in various industries. They offer a range of services including DNA tagging, authentication, and tracking of products to prevent counterfeiting and fraud. The company's main focus is on industries such as textiles, pharmaceuticals, and supply chain, where their DNA-based solutions have the potential to revolutionize how products are verified and protected. Applied DNA Sciences Inc strives to provide innovative and secure solutions that give businesses and consumers peace of mind in the authenticity of their products.


   Company Address: 50 Health Sciences Drive Stony Brook 11790 NY
   Company Phone Number: 240-8800   Stock Exchange / Ticker: NASDAQ APDN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
IEHC        2% 
CRL   -2.43%    
DGX   -0.51%    
DMRC   -4.62%    
FLGT   -1.16%    
MXCT        0.92% 
• View Complete Report
   



Applied Dna Sciences Inc

Financial Crisis Looms for Applied DNA Sciences Inc as Revenue Plummets in Second Quarter of 2024

Applied DNA Sciences Inc, a leading provider of DNA-based security solutions, recently released its second quarter financial report for 2024, painting a less than ideal picture for the company. The report revealed a disappointing -78.909% decline in revenue, which dropped to a mere $0.93 million. Moreover, the shortfall per share also expanded to a staggering $-5.31, compared to the same reporting period the previous year.
In a slight silver lining, the revenue did witness a sequential increase of 4.316% from the preceding reporting period, starting at $0.89 million. However, this minor growth did not make up for the overall loss in revenue experienced by the company.

Applied Dna Sciences Inc

Applied Dna Sciences Inc experiences mixed results in Q1 2024, with positive developments overshadowed by revenue decline

The financial results of Applied Dna Sciences Inc for the first quarter of 2024 paint a mixed picture, with both positive and negative aspects to consider.
Facts:
- Loss per share decreased from $-0.30 to $-0.09 compared to a year ago, indicating an improvement in the company's bottom line.
- Earnings per share also showed improvement, increasing from $-0.21 in the previous reporting period.
- Revenue saw a significant decrease of -83.067% to $0.89 million from $5.26 million in the comparable reporting period a year prior. However, revenue surged by 50.091% sequentially from $0.59 million.
- Applied Dna Sciences Inc reported a net shortfall of $-1.130 million in the first quarter of 2024, a significant improvement from the deficit of $-3.844 million in the same period a year ago.
- Stockpiles increased to $0.4 million, though still below the previous year's level of $0.5 million.
- The value of accounts receivable is lower than the previous year, but there has been some sequential progress.
Context:
- Applied Dna Sciences Inc shares have seen a 6.25% drop in the last five trading days, contributing to a year-to-date performance of -7.4%.
- Shares are currently trading only 10.6% above their 52-week low, suggesting that the company may be facing some challenges in the market.

Applied Dna Sciences Inc

Extremely difficult quarter for Applied Dna Sciences Inc in the most recent fiscal period



Applied DNA Sciences Inc, a company specializing in Electronic Instruments & Controls, recently disclosed its financial performance for the period ending September 30, 2023. The results showcased significant declines in revenue and a widening net deficit per share compared to the previous year. These developments, coupled with a decline in stock prices and a decrease in stockpiles, indicate challenging times ahead for the company.
Declining Financial Results:
During the past five days, Applied DNA Sciences Inc stock experienced a substantial decline of 26.14%. Furthermore, the stock's value dropped by 23.45% compared to the previous year. It is currently trading on NASDAQ, 12% below its 52-week average. These figures paint a grim picture for the company's immediate prospects.

Applied Dna Sciences Inc

Shocking Decline: Professional Services Giant Witnessed Abysmal Revenue Crash, Crushing April-June 2023 Interval!

Applied DNA Sciences Inc. is a company that specializes in providing molecular-based security and authentication solutions to various industries. They utilize unique DNA markers to ensure the integrity and traceability of products, with applications ranging from supply chain security to anti-counterfeiting measures.
However, the latest financial report for the company may raise some concerns for investors. From April to June 30, 2023, Applied DNA Sciences Inc. experienced a significant increase in their loss per share, with it reaching $-0.24 per share compared to $-0.13 per share in the previous year. Additionally, their income per share fell from $0.05 per share in the prior reporting period.

Applied Dna Sciences Inc

Applied DNA Sciences Inc. Shows Remarkable Financial Turnaround, Turning Losses into Profits in Q1 2023

Applied Dna Sciences Inc (APDN) has seen a significant turnaround in its financial performance in the period ending March 31, 2023. Despite a decline in revenue of 28.3% to $4.41 million, APDN managed to post positive earnings per share of $0.05 compared to a loss of $0.23 per share a year prior. The EPS turned positive from $-0.30 per share in the preceding quarter, indicating a clear upward trend in performance.
APDN's net profits of $0.551 million in the financial period ending March 31, 2023, is a vast improvement from the net deficit of $-1.760 million in the same quarter a year ago. These results suggest that the company's management has made significant strides in restructuring and improving its financial operations.







Applied Dna Sciences Inc's Segments
Research and development services (over-time)    7.51 % of total Revenue
Clinical laboratory testing services (point-in-time)    1.65 % of total Revenue
Clinical laboratory testing services (over-time)    39.07 % of total Revenue
Supply chain    24.33 % of total Revenue
Large Scale DNA Production    27.44 % of total Revenue
Product revenues    30.93 % of total Revenue
Service revenues    28.36 % of total Revenue
Clinical laboratory service revenues    40.72 % of total Revenue
Therapeutic DNA Production    34.95 % of total Revenue
MDx Testing Services    40.72 % of total Revenue
DNA Tagging and Security Products    24.33 % of total Revenue
Operating segment Product revenues    30.93 % of total Revenue
Operating segment Service revenues    28.36 % of total Revenue
Operating segment Therapeutic DNA Production Product revenues    27.44 % of total Revenue
Operating segment Therapeutic DNA Production Service revenues    7.51 % of total Revenue
Operating segment MDx Testing Services Clinical laboratory service revenues    40.87 % of total Revenue
Operating segment DNA Tagging and Security Products Product revenues    3.48 % of total Revenue
Operating segment DNA Tagging and Security Products Service revenues    20.85 % of total Revenue
Less intersegment revenues MDx Testing Services    -0.15 % of total Revenue
Product revenues    30.93 % of total Revenue
Service revenues    28.36 % of total Revenue
Therapeutic DNA Production Product revenues    27.44 % of total Revenue
Therapeutic DNA Production Service revenues    7.51 % of total Revenue
MDx Testing Services Clinical laboratory service revenues    40.87 % of total Revenue
DNA Tagging and Security Products Product revenues    3.48 % of total Revenue
DNA Tagging and Security Products Service revenues    20.85 % of total Revenue
Less interrevenues MDx Testing Services    -0.15 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com